DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

BIBLIOGRAPHY
Blanchard RL, Freimuth RR, Buck J, et al. A proposed
nomenclature system for the cytosolic sulfotransferase (SULT)
superfamily. Pharmacogenetics, 2004, 14:199–211.
Cashman JR. The implications of polymorphisms in mammalian
flavin-containing monooxygenases in drug discovery and
development. Drug Discov Today, 2004, 9:574–581.
Chen C, Gonzalez FJ, Idle JR. LC-MS-based metabolomics in
drug metabolism. Drug Metab Rev, 2007, 39:581–597.
Coughtrie MW. Sulfation through the looking glass—recent
advances in sulfotransferase research for the curious.
Pharmacogenomics J, 2002, 2:297–308.
Dutton GJ. Glucuronidation of Drugs and other Compounds.
CRC Press, Boca Raton, 1980.
Evans WE, Relling MV. Pharmacogenomics: Translating functional
genomics into rational therapeutics. Science, 1999, 286:487–491.
Glatt H. Sulfotransferases in the bioactivation of xenobiotics.
Chem Biol Interact, 2000, 129:141–170.
Golka K, Prior V, Blaszkewicz M, Bolt HM. The enhanced
bladder cancer susceptibility of NAT2 slow acetylators towards
aromatic amines: A review considering ethnic differences.
Toxicol Lett, 2002, 128:229–241.
Gong QH, Cho JW, Huang T, et al. Thirteen UDP
glucuronosyltransferase genes are encoded at the human UGT1
gene complex locus. Pharmacogenetics, 2001, 11:357–368.
Handschin C, Meyer UA. Induction of drug metabolism: the role
of nuclear receptors. Pharmacol Rev, 2003, 55:649–673.
Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases.
Annu Rev Pharmacol Toxicol, 2005, 45:51–88.
Kadakol A, Ghosh SS, Sappal BS, et al. Genetic lesions of
bilirubin uridine-diphosphoglucuronate glucuronosyltransferase
(UGT1A1) causing Crigler-Najjar and Gilbert syndromes:
Correlation of genotype to phenotype. Hum Mutat, 2000,
16:297–306.
Kinnings SL, Liu N, Buchmeier N, et al. Drug discovery using
chemical systems biology: Repositioning the safe medicine
Comtan to treat multi-drug and extensively drug resistant
tuberculosis. PLoS Comput Biol, 2009, 5:e100042.
Kobayashi K, Bouscarel B, Matsuzaki Y, et al. PH-dependent
uptake of irinotecan and its active metabolite, SN-38, by
intestinal cells. Int J Cancer, 1999, 83:491–496.
Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy:
getting personal. Am J Hum Genet, 1998, 63:11–16.
Landi S. Mammalian class theta GST and differential susceptibility
to carcinogens: A review. Mut Res, 2000, 463:247–283.
Lee KA, Fuda H, Lee YC, et al. Crystal structure of human
cholesterol sulfotransferase (SULT2B1b) in the presence of
pregnenolone and 3′- phosphoadenosine 5′-phosphate.
Rationale for specificity differences between prototypical
SULT2A1 and the SULT2BG1 isoforms. J Biol Chem, 2003,
278:44593–44599.
Meisel P. Arylamine N-acetyltransferases and drug response.
Pharmacogenomics, 2002, 3:349–366.
Negishi M, Pederson LG, Petrotchenko E, et al. Structure and
function of sulfotransferases. Arch Biochem Biophys, 2001,
390:149–157.
Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of
cytochrome P450 (CYP) genes from the mouse and human
genomes, including nomenclature recommendations for genes,
pseudogenes and alternative-splice variants. Pharmacogenetics,
2004, 14:1–18.
Nicholson JK, Connelly J, Lindon JC, Holmes E.
Metabonomics: A platform for studying drug toxicity and gene
function. Nat Rev Drug Discov, 2002, 1:153–161.
Pedersen LC, Petrotchenko E, Shevtsov S, Negishi M. Crystal
structure of the human estrogen sulfotransferase-PAPS
complex: evidence for catalytic role of Ser137 in the sulfuryl
transfer reaction. J Biol Chem, 2002, 277:17928–17932.
Strassburg CP. Pharmacogenetics of Gilbert’s syndrome.
Pharmacogenomics, 2008, 9:703–715.
Townsend DM, Tew KD. The role of glutathione-S-transferase in
anti-cancer drug resistance. Oncogene, 2003, 22:7369–7375.
Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases:
metabolism, expression, and disease. Annu Rev Pharmacol
Toxicol, 2000, 40:581–616.
Tukey RH, Strassburg CP, Mackenzie PI. Pharmacogenomics of
human UDP-glucuronosyltransferases and irinotecan toxicity.
Mol Pharmacol, 2002, 62:446–450.
Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for
Nacetyltransferases. Pharmacogenetics, 1995, 5:1–17.
Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation
pharmacogenetics: catechol O-methyltransferase, thiopurine
methyltransferase, and histamine N-methyltransferase. Annu
Rev Pharmacol Toxicol, 1999, 39:19–52.
Williams PA, Cosme J, Vinkovic DM, et al. Crystal structures of
human cytochrome P450 3A4 bound to metyrapone and
progesterone. Science, 2004, 305:683–686.
Yamamoto W, Verweij J, de Bruijn P, et al. Active transepithelial
transport of irinotecan (CPT-11) and its metabolites by
human intestinal Caco-2 cells. Anticancer Drugs, 2001,
12:419–432.
143
CHAPTER 6
DRUG METABOLISM